Comparison of Three Different A1Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs-Reference-Cited by-同舟云学术

Comparison of Three Different A1Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs

Published:2003-11-21 Issue:3 Volume:308 Page:846-856
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Auchampach John A.,Jin Xiaowei,Moore Jeannine,Wan Tina C.,Kreckler Laura M.,Ge Zhi-Dong,Narayanan Jayashree,Whalley Eric,Kiesman William,Ticho Barry,Smits Glenn,Gross Garrett J.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference39 articles.

1. Isolation of plasma membrane fractions from the intestinal epithelial model T84

2. Canine Mast Cell Adenosine Receptors: Cloning and Expression of the A3 Receptor and Evidence that Degranulation Is Mediated by the A2B Receptor

3. Selective Activation of A3Adenosine Receptors WithN6-(3-Iodobenzyl)Adenosine-5′-N-Methyluronamide Protects Against Myocardial Stunning and Infarction Without Hemodynamic Changes in Conscious Rabbits

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Hypoxia-Adenosine Link during Myocardial Ischemia—Reperfusion Injury;Biomedicines;2022-08-10

2. Novel non-xanthine antagonist of the A2B adenosine receptor: From HTS hit to lead structure;European Journal of Medicinal Chemistry;2019-02

3. Structures of Human A 1 and A 2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity;Structure;2017-08

4. Adenosine A2A and A2B Receptor Substantially Attenuate Ischemia/Reperfusion Injury in Septic rat Hearts;Cardiovascular Drugs and Therapy;2016-10-18

5. Dual A1/A2B Receptor Blockade Improves Cardiac and Renal Outcomes in a Rat Model of Heart Failure with Preserved Ejection Fraction;Journal of Pharmacology and Experimental Therapeutics;2015-11-19